Oligodendrocyte Progenitor Cell Culture From Human Brain

This study is currently recruiting participants.

Verified by Rajavithi Hospital, August 2008

First Received: January 25, 2006 Last Updated: August 2, 2008 History of Changes

Sponsor:	Rajavithi Hospital
Information provided by:	Rajavithi Hospital
ClinicalTrials.gov Identifier:	NCT00283023

Purpose

Recent developments in the understanding of stem- and progenitor cell differentiation raises hopes that brain damage in chronic neurological diseases may become repaired by systemic or focal transplantation of such cells. Clinical trials of stem- or progenitor cell transplantation in multiple sclerosis are currently premature. The researchers developed a protocol for human oligodendrocyte progenitor cell culture from human brain for the treatment of demyelinating disease.

Condition	Intervention	Phase
Demyelinating Diseases	Procedure: Oligodendrocyte progenitor cell culture/craniotomy	Phase I

Study Type:	Interventional
Study Design:	Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study
Official Title:	Phase 1: Oligodendrocyte Progenitor Cell Culture From Human Brain

Further study details as provided by Rajavithi Hospital:

Primary Outcome Measures:

Number of oligodendrocyte progenitor cell differentiation [ Time Frame: one month ] [ Designated as safety issue: No ]

Estimated Enrollment:	100
Study Start Date:	December 2007
Estimated Primary Completion Date:	December 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
A: Experimental Progenitor cells from the patinets with Craniotomy with V-P Shunt or ventriculostomy will be collected and cultured.	Procedure: Oligodendrocyte progenitor cell culture/craniotomy Oligodendrocyte progenitor cell culture protocol of Rajavithi Hospital will be apply

Detailed Description:

Oligodendrocyte progenitor cell line were cultures and will be transplanted into the patient with Multiple sclerosis.

Eligibility

Ages Eligible for Study:	20 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Male or female 20-65 years of age
Informed consent
Has elective craniotomy surgery

Exclusion Criteria:

HIV, hepatitis, and other central nervous system (CNS) infections
Dementia, Alzheimer disease, and neurodegenerative disease

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00283023

Contacts

Contact: Subsai Kongsaengdao, M.D.

+66-6-6596159

skhongsa@gmail.com

Locations

Thailand
Assistant Professor Subsai Kongsaengdao	Recruiting
Bangkok, Thailand, 10400
Contact: Subsai Kongsaengdao, M.D. 66-86-6596159 skhongsa@gmail.com
Contact: Piyathida Boontee, M.D. 66-81-8423854 pboontee@yahoo.com

Sponsors and Collaborators

Rajavithi Hospital

Investigators

Principal Investigator:

Subsai Kongsaengdao, M.D.

Division of Neurology, Department of Medicine, Rajavithi Hospital : Thailand

More Information

No publications provided

Responsible Party:	Rajavithi Hospital ( Assistant Professor Subsai Kongsaengdao )
Study ID Numbers:	RH-CMR-003, RVH-CMR-003 grant
Study First Received:	January 25, 2006
Last Updated:	August 2, 2008
ClinicalTrials.gov Identifier:	NCT00283023 History of Changes
Health Authority:	Thailand: Ministry of Public Health

Keywords provided by Rajavithi Hospital:

All selective craniotomy

Additional relevant MeSH terms:

Demyelinating Diseases
Nervous System Diseases

ClinicalTrials.gov processed this record on November 30, 2009